OBJECTIVES: To analyze the prevalence of local antiglaucoma medicines in drug-store of Russia and to make the pharmaeconomical research on the base of large statistical selection. METHODS: In 2003, the total cost of antiglaucoma medicines sales in drug-stores of Russia was about 10.86m USD. The beta-blockers took the first place ($7.0m or 64.4%. The pilocarpine analogue medicines took the second place. Their joint sales volume was $1.8m or 16.7%. Two combined medicines Fotil and Fotil forte (Santen) were at the third place $1.2m (10.7%). Latanoprost (Xalatan, Pharmacia-Pfizer) and Brinzolamide (Azopt, Alcon) began to be saled more active. The sales of the first, in 2003, were 3.8%. Azopt began to be saled only in 2002 and its results are $147,878.15 or 1.35% and in 2003 - $289,265 (2.7%) The other CAI Trusopt (MSD) was pharmacoeconomical in 2002 on $217,473.86 (1.99%) and in 2003 $184,713 (1.7%). The portion of all other medicines in 2002 was less than 0.5%. The average price of beta-blocers is 0.7-$2.1, CAIs about $22; prostaglandins and their combination (Xalacom, Pfizer - sales started only in the end of 2002 year in Russian market) $25.6 and $26.9; combined form (timolol+pilocarpine) $5; pilocarpine $0.83 round the clock and the course of treatment during a one year is $11.92 (pilocarpine) $380.32 (Trusopt). RESULTS: The timolol maleate, pilocarpine and their combination are medicines of choice for treatment of glaucoma in Russia. CONCLUSIONS: More attention is being payed to prostaglandins and CAIs. The information of ophthalmologist and their patients about the cost of therapy is a very important component for pharmaeconomical decisions together with medical effectiveness of treatment. But it is rather low in Russia in whole.